According to our recent payer coverage analysis for chronic heart failure treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: While differentiation between channels is less significant than in other highly managed classes, commercial formularies are quite clearly the least restrictive to chronic heart attack and heart failure products.
Source: MMIT data as of Q3 2016
Trends: One example of new technological innovation - the creation of a virtual model that can test pharmaceuticals based on patient scenarios to prevent adverse events - could drastically improve the success of treatments when used appropriately. Additionally, new research shows the challenges for congestive heart failure prescribers with an average heart failure patient taking an average of 7 medications that could result in dangerous adverse events.
To read the full Reality Check on chronic heart failure treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: